Loading…

Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to a paucity of effective targeted therapies. Many studies have reported that breast cancer stem cells (BCSCs) are enriched in TNBC and are responsible for chemoresistance and metastasis. In this study,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2018-12, Vol.438, p.165-173
Main Authors: Lin, Chang-Ching, Lo, Miao-Chia, Moody, Rebecca, Jiang, Hui, Harouaka, Ramdane, Stevers, Nicholas, Tinsley, Samantha, Gasparyan, Mari, Wicha, Max, Sun, Duxin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple-negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to a paucity of effective targeted therapies. Many studies have reported that breast cancer stem cells (BCSCs) are enriched in TNBC and are responsible for chemoresistance and metastasis. In this study, we identify LRP8 as a novel positive regulator of BCSCs in TNBC. LRP8 is highly expressed in TNBC compared to other breast cancer subtypes and its genomic locus is amplified in 24% of TNBC tumors. Knockdown of LRP8 in TNBC cell lines inhibits Wnt/β-catenin signaling, decreases BCSCs, and suppresses tumorigenic potential in xenograft models. LRP8 knockdown also induces a more differentiated, luminal-epithelial phenotype and thus sensitizes the TNBC cells to chemotherapy. Together, our study highlights LRP8 as a novel therapeutic target for TNBC as inhibition of LRP8 can attenuate Wnt/β-catenin signaling to suppress BCSCs. •Higher expression of LRP8 is associated with TNBC and poor prognosis.•Knockdown of LRP8 suppresses BCSCs in TNBC via inhibiting Wnt/β-catenin signaling.•Targeting LRP8 shifts TNBC cells to a more differentiated, epithelial cell state.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2018.09.022